Vladimirs Strazdins et al., J Nephrol Ther 2018, Volume 8
DOI: 10.4172/2161-0959-C2-054

Recurrent urinary tract infections in adults in Latvia: Additional findings from 2014 study

Vladimirs Strazdins[1] and **Harijs Cernevskis**[2]
[1]Medical Society Gailezers Ltd., Latvia
[2]Pauls Stradiš Clinical University Hospital, Latvia

Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception. Furthermore, the recent trends may prohibit the further use of fluoroquinolones in UTI treatment. Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary. This observational study was comprised in July-November 2014, when family physicians across Latvia submitted the anonymous patient data on recurrent UTI treatment in their practice. Bacterial flora spectrum in Latvian adult recurrent UTI population was fairly consistent with data from other European countries, with prevalent Escherichia coli cultures. The soluble nitrofuran derivate (NFD) - in Latvia Furamags ® in particular was clinically effective in all patients, even in culture-negative or NFD-resistant patients. There was not a single case without any improvement in controlled parameters – Furamags ® was clinically effective in all cases, including pyelonephritis. This confirms unique multifactorial antibacterial activities of NFDs, which simultaneously inhibit protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis and cell-wall synthesis, thus ensuring antibacterial activity even against the seemingly resistant flora. The current first-choice empiric treatment of recurrent UTI by NFDs may stay unchanged. Particular NFD used in Latvia (Furamags ®) is safe, well-tolerated and effective first-line UTI (including pyelonephritis) treatment choice.

Biography

Vladimirs Strazdins completed his Graduation from Riga Stradins University in 1977 and dedicated his further carrier to nephrology and pediatric nephrology. From 1992 till 2009, he worked as a Head of Nephrology at University Hospital for Children in Riga. From 2004 till 2012, he was a member of European Pediatric Dialysis working group, participating in creation of European guidelines on the subject. In 1999, he was awarded with Special Recognition Award for developing the pediatric ESRD treatment program in Latvia and Lithuania; in 2013 awarded with Honor Medal Tempus Hominis 2nd degree for outstanding achievements in medicine.

voldis@outlook.lv

Notes: